

HTRF® Research Reagents

## Anti phospho PKC substrate-K Quality Control

Product number : 61P03KAE Lot Number : 07RA

Manufacturing date : 03/08/2018 Document version : 1

### EXPERIMENTAL CONDITION

The batch to be controlled was compared to the reference batch currently in use, at increasing Peptide Biotin-PO4 (n° 1148) concentrations and at decreasing Peptide Biotin- non PO4 (n° 1147) concentrations.

Anti phospho PKC substrate -K is frozen in Hepes buffer 50 mM pH 7, 0.1% BSA.

All the reagents involved were diluted in PPI-Europium detection buffer (#61DB9RDF).

### ASSAY FORMAT

Anti phospho PKC substrate -K + Peptide Biotin-PO4 and Peptide Biotin-non PO4 + SA-XL<sup>ent!</sup>

### REAGENTS

|   | REFERENCE LOT NUMBER | ASSAY CONCENTRATION            |
|---|----------------------|--------------------------------|
| SA-XL ent!                              | 24B                  | 5 nMf                          |
| Anti phospho PKC substrate -K reference | 06                   | 145 ng/mLf                     |
| Peptide Biotin-PO4 (n° 1148)            | CQ01                 | 10 nMf (gradient de 0% à 100%) |
| Peptide Biotin-non PO4 (n° 1147)        | CQ01                 | 10 nMf (gradient de 100% à 0%) |

|  | CURRENT BATCH LOT NUMBER | ASSAY CONCENTRATION |
|--|--------------------------|---------------------|
| Anti phospho PKC substrate-K current batch | 07RA                     | 145 ng/mLf          |

Other reagents were the same as those used for the reference test.

If applicable, streptavidin / biotin ratio was set up at : 1/2

### EXPERIMENTAL PROCEDURE

Reagents were dispensed as follows :

- 10 µL Peptide Biotin-PO4 and Peptide Biotin-non PO4
- 5 µL XL conjugate
- 5 µL K conjugate


Incubation took place for 150 min at room temperature. The plate was read on Phera Star under standard conditions.

## RESULTS

| Peptide Biot-PO4<br>(n°1148)<br>% |                   | Anti phospho<br>PKC substrate-K<br>Reference | Anti phospho PKC<br>substrate-K<br>CURRENT<br>BATCH | VARIATION | MEAN<br>ACCEPTABLE<br>VARIATION |
|-----------------------------------|-------------------|--|---|-----------|---------------------------------|
| 5                                 | % Delta F<br>% CV | 236 %<br>0.4 %                               | 501 %<br>1.3 %                                      | 112 %     | 230 %                           |
| 10                                | % Delta F<br>% CV | 269 %<br>0.7 %                               | 874 %<br>0.2 %                                      | 225 %     |                                 |
| 20                                | % Delta F<br>% CV | 274 %<br>0.8 %                               | 1005 %<br>2.7 %                                     | 267 %     | ± 20* %                         |
| 50                                | % Delta F<br>% CV | 284 %<br>0.3 %                               | 1014 %<br>2.9 %                                     | 257 %     |                                 |
| 100                               | % Delta F<br>% CV | 288 %<br>3.2 %                               | 1117 %<br>0.4 %                                     | 288 %     |                                 |

\*New antibody

For the batch release, variation in delta F must be less than 20 %.



Anti phospho PKC substrate-K batch # 07RA

Accepted



Rejected



Operator's initials: MB

Date : 03/08/2018

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

revvity